Ramipril

Chemical formula: C₂₃H₃₂N₂O₅  Molecular mass: 416.511 g/mol  PubChem compound: 5362129

Therapeutic indications

Ramipril is indicated for:

Hypertension

Population group: only adults (18 years old or older)

Hypertension

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Symptomatic heart failure

Population group: only adults (18 years old or older)

Symptomatic congestive heart failure

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Secondary prevention after acute myocardial infarction

Population group: only adults (18 years old or older)

Reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started >48 hours following acute myocardial infarction.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Renal disease in patients with diabetes and microalbuminuria

Population group: only adults (18 years old or older)

Incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Cardiovascular prevention

Population group: only adults (18 years old or older)

Reduction of cardiovascular morbidity and mortality in patients with:

  • manifest atherothrombotic cardiovascular disease (history of coronary heart disease or stroke, or peripheral vascular disease) or
  • diabetes with at least one cardiovascular risk factor.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Renal disease in patients with diabetes and at least one cardiovascular risk

Population group: only adults (18 years old or older)

Manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Renal disease in patients with non-diabetic nephropathy as defined by macroproteinuria ≥3 g/day

Population group: only adults (18 years old or older)

Kidney disease and additionally not Diabetic renal disease

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Ramipril is contraindicated in the following cases:

Aliskiren in diabetes mellitus or renal impairment

Aliskiren and additionally at least one of
Diabetes mellitus



Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

Pregnancy

Pregnancy

History of angioedema

at least one of
Idiopathic angio-oedema
Hereditary angioneurotic edema
ACE inhibitor-aggravated angio-oedema

Sacubitril/valsartan

Valsartan and sacubitril

Renal artery stenosis

RAS - Renal artery stenosis

Hypotensive or haemodynamically unstable states

at least one of
Hypotension
Haemodynamic instability

Extracorporeal treatments leading to contact of blood with negatively charged surfaces

Extracorporeal circulation procedure

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Structured Product Labeling (SPL/PLR) 2020: ALTACE Capsule
Summary of Product Characteristics (SPC) 2024: RAMIPRIL Capsule, hard
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈